ScanGlean
Take the Fit Check Fit Check

Blog

Your Full-Body MRI Found Something. Now What? A Finding-by-Finding Guide (2026)

ScanGlean Editorial Team · September 26, 2026 · 28 min read

The notification usually arrives at a bad time. You open the patient portal — maybe on your phone, maybe late at night — and the report you paid $1,000 to $4,000 for says something like “2.1 cm T2-hyperintense lesion in the left kidney. Recommend follow-up.” Or “indeterminate 8 mm pancreatic cyst.” Or “subcentimeter thyroid nodule.”

You didn’t have symptoms. You did this to feel reassured. And now there’s something in your body with a name you can’t pronounce.

A radiologist at Weill Cornell put the problem precisely in a July 2026 interview with RSNA News: “You don’t want people logging on to a portal at 11 p.m., seeing their report with a finding they’re unsure of and rushing to the ER.” This guide exists for that moment. It’s built for people who have already had a Prenuvo, Ezra, SimonMed, or other whole-body MRI and are staring at a finding — and for anyone deciding whether to book one, who deserves to know what that moment is likely to look like.

We’ll go through how common findings are, how to decode the language in your report, what the most frequent findings typically mean according to published radiology guidelines, who pays for follow-up, and the insurance consequence almost nobody mentions before the scan. We don’t sell scans and have no relationship with any scan provider.

TL;DR

  • A finding is the normal result, not the exception. Screening whole-body MRIs report at least one finding in 78%–97% of people; roughly 10%–25% are clinically significant, and confirmed cancer rates run about 1%–2%.
  • Most common findings have a published playbook. The American College of Radiology (ACR), the Fleischner Society, and the Bosniak system tell clinicians exactly when a kidney cyst, liver spot, thyroid nodule, adrenal nodule, or pancreatic cyst needs follow-up — and, just as often, when it doesn’t.
  • Follow-up is usually billed to your health insurance as diagnostic care, even though the scan itself wasn’t covered. Expect deductibles and possible prior authorization.
  • Life, disability, and long-term care insurance are different. Unlike health insurance, they aren’t bound by the ACA’s pre-existing-condition protections, and a pending workup can postpone an application.
  • Your next step is almost never the ER. It’s a calm review of the full report with your own doctor, anchored to the guideline for your specific finding.

The Short Answer: What to Do in the First 48 Hours

If you only read one section, read this one.

  1. Find the recommendation line. Every finding in a good report ends with one of three instructions: no follow-up needed, follow-up recommended (non-urgent), or urgent/prompt follow-up. That single line tells you more than the rest of the paragraph. If the provider considered a finding urgent, they generally contact you directly rather than leaving it in a portal.
  2. Download the full report and request your images. You’ll need the images (in DICOM format) for any second opinion or comparison later.
  3. Book a visit with your own primary care doctor — not just the scan company’s consultant. Your doctor knows your history, can order follow-up under your insurance, and is the person who will close the loop.
  4. Look up the guideline for your finding (below), so you walk in knowing what “normal” follow-up looks like.
  5. Ask what the end point is. “What result would tell us we’re done?” is the most calming question in medicine.

Still deciding whether a scan is right for you in the first place? See which guideline-backed screenings you actually qualify for — colonoscopy, coronary calcium scoring, lung cancer screening, and more. Take the Fit Check →

How Common Is It for a Full-Body MRI to Find Something?

Here’s the number that should reframe everything: finding something is the expected outcome.

  • A 2026 paper in Radiology Advances by radiologists at Weill Cornell, describing how they built an academic whole-body MRI screening program, summarized the literature: reportable findings occur in 78% to 97% of screening whole-body MRIs, with approximately 10% to 25% deemed clinically significant. Their own early data — about 160 patients in the first 18 months, as reported by RSNA News — matched that pattern: roughly 90% had some finding, about 30% had a finding that “was not inherently worrisome but required follow-up,” and about 1% had findings that were malignant or suspected malignant.
  • A 2019 systematic review in the Journal of Magnetic Resonance Imaging (Kwee and colleagues; 12 studies, 5,373 asymptomatic adults) found a pooled 32.1% prevalence of “critical” or “indeterminate” findings. Among studies that tracked what happened next, a pooled 16% of flagged findings were false positives — though the authors stressed that verification data were thin.
  • The largest meta-analysis, published in The BMJ in 2018 (Gibson and colleagues; 32 studies, 27,643 people), found potentially serious incidental findings in 3.9% of combined brain-and-body MRIs, rising to 12.8% once findings of “uncertain” seriousness were included. The most important number is this one: where outcomes were actually tracked, only 48 of 234 (20.5%) potentially serious findings ended up with a serious final diagnosis.

Put differently: if your report lists a finding, you are in the majority. If your report lists a finding flagged for follow-up, you’re in a large minority — and most people in that group end up with a benign answer.

Why a Finding Feels So Much Worse Than It Usually Is

It’s worth naming what’s happening in your head, because it shapes the decisions you make next.

You were primed for a verdict, not a probability. Full-body scans are sold on a story of certainty — “know what’s going on inside you.” A report that says “indeterminate” breaks that promise, and uncertainty is, for most people, more distressing than a known bad outcome. That’s why the waiting period often feels worse than the eventual answer.

“Lesion,” “mass,” and “enhancement” are neutral words that don’t sound neutral. In radiology, “lesion” simply means an area that looks different from its surroundings. A harmless cyst is a lesion. So is a birthmark-like blood vessel cluster in the liver.

Search engines surface the frightening outcome. Type “pancreatic cyst” into a search bar and pancreatic cancer dominates the results — even though, as we’ll see below, pancreatic cysts show up on roughly 1 in 5 MRIs of people in their 60s.

The worry can outlast the all-clear. This isn’t a reason to feel foolish — it’s documented. In a Danish cohort study published in the Annals of Family Medicine in 2013, women who received a false-positive mammogram still reported more negative psychosocial effects three years after being told they didn’t have cancer than women with normal results. Dr. Thomas Kwee of the University of Groningen, whose systematic review is cited above, told RSNA News: “When people know there is something in their body that should not be there, it affects their work and social life.”

None of this means you should ignore a finding. It means the goal is to get to a resolved answer efficiently — without letting a cascade of unnecessary tests become its own harm. In a 2019 national survey of U.S. internists in JAMA Network Open, 99.4% reported having seen a “cascade” of tests and visits triggered by an incidental finding, and they described psychological, physical, and financial harm to patients as a result.

How to Read the Language in Your MRI Report

Radiologists hedge because images genuinely can’t always tell benign from malignant. But hedge words aren’t random. Mass General Brigham’s radiology department publishes a standardized “diagnostic certainty scale” that maps phrases to rough probabilities, building on an earlier lexicon proposed in the American Journal of Roentgenology by Panicek and Hricak (2016):

Phrase in your report Approximate probability the radiologist means
“Most likely” / “consistent with” Greater than 90%
“Likely” About 75%–90%
“May represent” / “possibly” About 25%–75%
“Unlikely” About 5%–25%
“Very unlikely” Less than 5%

Not every radiologist uses this exact scale, but it’s a reasonable decoder. If your report says a lesion “most likely represents a hemangioma,” the radiologist is telling you they’re highly confident it’s benign.

A few other phrases worth translating:

  • “Incidental” — found by chance, unrelated to any symptom. It says nothing about whether it’s dangerous.
  • “Too small to characterize” — it’s tiny enough that the scan can’t tell what it is. For many organs, guidelines treat tiny lesions in low-risk people as almost always benign.
  • “Indeterminate” — the images can’t settle it. This is where a single targeted follow-up test (a different MRI sequence, an ultrasound) usually provides the answer.
  • “Clinical correlation recommended” — the meaning depends on your history, symptoms, or labs. It’s a note to your doctor, not a hidden alarm.
  • “No prior imaging for comparison” — a big one for screening scans. Stability over time is one of the strongest signs of benignity, and a first-ever scan has nothing to compare against. That’s why many findings get a follow-up scan simply to prove they’re not changing.

The Most Common Full-Body MRI Findings, and What Guidelines Say to Do

The Weill Cornell group lists the most frequent actionable findings on screening whole-body MRI as complex kidney cysts or masses (1.7%–5.3% of scans), liver lesions (2.5%–11%), ovarian cysts (2.6%–6.3%), thyroid nodules (2.2%–6.8%), and adrenal nodules (0.8%–1.7%). Below is what each typically means — and what the published professional guidance says clinicians should do.

Important: this is how guidelines approach typical cases in people without symptoms or a relevant cancer history. Your own doctor may reasonably deviate from them based on your risk factors.

At a Glance

Finding How common Usual meaning Typical next step (per guideline)
Kidney cyst Roughly 1 in 4 adults over 50 on CT Almost always a benign fluid sac Bosniak I–II: none. IIF: imaging over 5 years. III–IV: urology
Liver lesion 2.5%–11% of screening WB-MRIs Usually a cyst or hemangioma Characteristic benign features or under 1 cm in low-risk adults: usually none
Thyroid nodule Up to ~68% of adults on high-resolution ultrasound Overwhelmingly benign Ultrasound only if ≥1.5 cm (age 35+) or ≥1 cm (under 35), or suspicious features
Pancreatic cyst ~9% of 3T MRIs; ~19% in people in their 60s Usually benign or slow-growing Periodic imaging, interval set by size; specialist if worrisome features
Adrenal nodule 0.8%–1.7% of screening WB-MRIs Usually a benign adenoma Fat-containing on MRI: benign; hormone screening blood test
Ovarian cyst 2.6%–6.3% of screening WB-MRIs Usually a normal cycle follicle Simple cyst under 3 cm before menopause: none
Brain findings Aneurysm ~1.8%, meningioma ~0.9% (Rotterdam) Often stable for years Specialist review; many are monitored, not treated
Spine “degeneration” 37% at age 20 to 96% at age 80 Normal aging None unless symptoms

Kidney Cysts

What it usually is: a fluid-filled sac on the kidney, extremely common with age. A study from the 1980s found renal cysts on CT in at least 27% of patients aged 50 and over, and later reviews estimate that as many as half of people have one by age 60.

The playbook: radiologists use the Bosniak classification, updated in 2019 to formally include MRI. Bosniak I (simple) and II cysts are benign and need no follow-up. Bosniak IIF (“F” for follow-up) cysts are imaged at 6 and 12 months, then yearly for five years in total; the large majority are benign, and those that aren’t are nearly always slow-growing. Bosniak III has an intermediate probability of malignancy, and Bosniak IV (up to 90% malignant) warrants urology consultation.

What to ask: “What Bosniak category is this?” If the report doesn’t say, ask whether it can be classified — that one label determines almost everything that follows.

Liver Lesions (Cysts and Hemangiomas)

What it usually is: a simple liver cyst or a hemangioma — a benign tangle of blood vessels that is the most common non-cancerous liver tumor. MRI is actually quite good at recognizing both.

The playbook: the ACR’s 2017 white paper on incidental liver lesions divides patients by risk. “Low-risk” means no known cancer, no liver disease, and no liver risk factors. In low-risk adults, lesions with clearly benign features — or lesions under about 1 cm that are too small to characterize — generally need no further workup. Larger indeterminate lesions get a dedicated liver MRI with contrast.

Worth knowing: a whole-body MRI may also comment on fat in the liver. That isn’t an “incidentaloma” in the scary sense — it’s a potentially useful signal about metabolic health that’s worth discussing with your doctor alongside blood sugar, lipids, and weight.

Thyroid Nodules

What it usually is: thyroid nodules are so common that a 2009 study using high-frequency ultrasound found them in 68% of adults examined. The large majority are benign.

The playbook: MRI is poor at judging thyroid nodules; ultrasound is the right test. But the ACR’s Incidental Thyroid Findings Committee recommends no further evaluation for nodules under 1.5 cm in people aged 35 or older, or under 1 cm in people under 35, unless there are suspicious features such as abnormal lymph nodes or signs of invasion.

Why guidelines are this conservative: South Korea’s experience is the textbook example. After thyroid ultrasound was widely added to screening, thyroid cancer diagnoses in 2011 were 15 times the 1993 rate — yet thyroid cancer deaths stayed flat, as reported in the New England Journal of Medicine in 2014. Many of those small cancers would never have caused harm. Finding more didn’t save more lives.

Pancreatic Cysts

What it usually is: this finding sounds the scariest and is usually far less dramatic than it sounds. A study of 2,583 patients scanned on 3-Tesla MRI (PLoS One, 2015) found incidental pancreatic cysts in 9.3% — rising steeply with age, from 1.2% of people under 40 to 12.1% in their 50s, 19.0% in their 60s, and about 31% after 70.

The playbook: the ACR’s 2017 white paper sets imaging surveillance intervals based on cyst size and features, often extending over many years. Stable cysts get less frequent imaging over time; growth or “worrisome features” (a solid component, a dilated pancreatic duct) trigger evaluation with endoscopic ultrasound and a specialist.

What to ask: “Are there any worrisome features, and what’s my surveillance schedule?” A small, simple, stable cyst on a clear schedule is a very different situation from what a midnight search suggests.

Adrenal Nodules

What it usually is: a benign adrenal adenoma. MRI has a specific trick for these: “chemical-shift” imaging detects microscopic fat, and a nodule that drops signal on opposed-phase images is almost always a benign, lipid-rich adenoma.

The playbook: per the ACR’s 2017 adrenal white paper, benign-appearing nodules don’t need further imaging, but the patient should get a simple hormone evaluation to rule out a nodule that overproduces cortisol or other hormones. That’s usually blood or urine testing — not more scans.

Ovarian Cysts

What it usually is: in anyone still menstruating, a cyst on the ovary is often just the normal follicle or corpus luteum of that month’s cycle — an expected, temporary structure.

The playbook: the ACR’s 2020 white paper on incidental adnexal findings (aligned with O-RADS and Society of Radiologists in Ultrasound guidance) says simple-appearing cysts carry very low malignancy risk, and that routine follow-up generally isn’t needed for simple cysts under 3 cm in premenopausal women. Larger cysts, or any cyst after menopause, are more often followed with ultrasound.

Lung Nodules

Worth knowing first: MRI is weaker than CT at seeing small lung nodules, so this finding on a whole-body MRI often leads to a CT to characterize it. The widely used Fleischner Society 2017 guidelines (written for CT) state that solid nodules under 6 mm in low-risk adults generally need no routine follow-up, because the cancer risk is well under 1%. If you smoke or used to smoke heavily, the calculus changes — and you may qualify for guideline-recommended annual low-dose CT lung screening regardless of any MRI.

Brain Findings

The landmark population study here is the Rotterdam Scan Study (New England Journal of Medicine, 2007): 2,000 people, average age 63, all without symptoms. Researchers found silent brain infarcts (old, small strokes) in 7.2%, aneurysms in 1.8%, and benign tumors in 1.6% — mostly meningiomas, found in 0.9%.

That’s a reminder of how much “normal” brains contain. Small meningiomas are frequently just monitored; small unruptured aneurysms are assessed by a neurovascular specialist, who weighs size, location, and your risk factors before deciding between monitoring and treatment. White-matter spots are very common with age and blood pressure — which makes them a useful prompt to check your blood pressure, not a diagnosis.

Spine “Degeneration”

If your report describes disc bulges, disc degeneration, or annular fissures: a 2015 systematic review in the American Journal of Neuroradiology found disc degeneration in 37% of pain-free 20-year-olds and 96% of pain-free 80-year-olds, and disc bulges in 30% rising to 84%. The authors’ conclusion: many of these features are “likely part of normal aging and unassociated with pain.” Without symptoms, these findings typically need nothing.

When a Finding Genuinely Needs Prompt Attention

Most findings don’t — but some do, and it’s important to recognize them rather than drift into complacency. Take these seriously and act within days, not months:

  • Wording like “suspicious for malignancy,” “concerning for,” or “solid enhancing mass.”
  • A kidney lesion categorized Bosniak III or IV.
  • A pancreatic cyst with “worrisome features” or “high-risk stigmata.”
  • An aortic aneurysm or significantly enlarged aorta, or any finding the report labels urgent or critical.
  • Any finding plus new symptoms — unexplained weight loss, bleeding, severe headache, neurological changes, or pain. Symptoms change the picture entirely; tell your doctor right away, and go to emergency care for anything that feels like an emergency.

Even in these cases, the right next step is usually a prompt specialist appointment or a targeted test, not a same-night ER visit — unless you have emergency symptoms.

Who Pays for Follow-Up After a Self-Pay Full-Body MRI?

This is one of the most-searched questions after a scan, and the answer surprises people.

The screening scan itself is almost never covered by U.S. insurance, because no major guideline body recommends whole-body MRI screening for average-risk adults. (Some people use HSA or FSA funds.)

But follow-up is usually ordinary diagnostic care. Once a finding exists, a follow-up ultrasound, dedicated MRI, CT, specialist visit, or biopsy is generally billed to your health insurance like any other diagnostic workup. That means:

  • Your deductible and coinsurance apply. The ACA’s no-cost-sharing rule covers specific preventive services, not diagnostic follow-up. (One narrow exception KFF Health News has reported on: a follow-up colonoscopy after a positive stool-based colon cancer screening test is now treated as part of the preventive screening.)
  • Prior authorization may apply, especially for advanced imaging. It goes more smoothly when the order comes from your own in-network clinician who documents the finding.
  • Network matters. A scan company’s affiliated specialist may be out of network for you.

How much does it add up to? The best population-level estimate comes from Germany’s SHIP cohort, published in BMJ Open. Over two years, people who had a whole-body MRI incurred about €295 (11.6%) more in outpatient costs than those who didn’t, driven mainly by extra imaging and specialist care. That’s an average — most people have little or no follow-up, and a few have a lot. The practical takeaway: before agreeing to any follow-up, ask whether it’s what the guideline for that finding recommends.

The Insurance Consequence Nobody Mentions Before the Scan

In the U.S., the Affordable Care Act means a health insurer can’t refuse you coverage or charge you more because of a pre-existing condition. A kidney cyst on your chart doesn’t change your health insurance.

That protection does not extend to life insurance, disability insurance, or long-term care insurance. Those are individually underwritten. Applications commonly ask about recent tests, abnormal results, and recommended-but-incomplete workups, and underwriters may check records and the MIB (an insurance-industry information exchange). When a finding is still unresolved, insurers often postpone an application — frequently for six months to a year — until the diagnosis is clear.

In one physician’s published account on Doximity, a patient was repeatedly denied life and disability insurance because an incidental heart finding sat in her chart — even though her cardiologist considered it clinically insignificant. The Weill Cornell team now lists “potential insurance implications” among the points they discuss with patients before a screening whole-body MRI.

Practical implications:

  • If you’re planning to buy term life, disability, or long-term care coverage anyway, consider doing it before an elective scan. Not to hide anything — you must answer every application question truthfully, and misrepresentation can void a policy — but because a pending workup can delay or complicate an offer.
  • If a finding already exists, finishing the workup helps. A documented benign resolution (“Bosniak II cyst, no follow-up needed”) reads very differently to an underwriter than an open-ended “indeterminate lesion.”

Your Questions for the Follow-Up Appointment

Bring these — written down, because anxiety erases memory:

  1. What exactly is this finding most likely to be, and how confident is the radiologist?
  2. Is there a published guideline for it, and what does it recommend for someone like me?
  3. What is the next test, and what could it show that would change what we do?
  4. What result would mean we’re finished with follow-up?
  5. Is this test covered by my insurance, and does it need prior authorization?
  6. Would a second read of the images by a subspecialist radiologist be worthwhile here?
  7. Is there anything in this report that’s useful for my general health — blood pressure, liver fat, bone health — that we should act on?

About second opinions: for an indeterminate finding or a recommended biopsy, a second read by an academic subspecialist radiologist can be well worth it. You’ll need the images, not just the report. Under HIPAA’s right of access, you’re generally entitled to a copy of your medical records, including imaging.

Getting Through the Wait

Waiting for a follow-up test is often the hardest part. A few things tend to help:

  • Pick one trusted source per finding — your doctor, or the guideline summary above — and stop searching. Every extra search mostly surfaces rare worst cases.
  • Get a date on the calendar. Uncertainty with a defined end is much easier to carry than open-ended uncertainty.
  • Remember the base rates. Most flagged findings on screening MRI turn out benign. In the BMJ meta-analysis, about 4 in 5 “potentially serious” findings that were followed up did not lead to a serious diagnosis.
  • Tell one person. Carrying a medical worry alone amplifies it.
  • If anxiety is affecting sleep, work, or relationships, say so to your doctor. That’s a real, documented harm of screening — not a character flaw — and it deserves care in its own right.

If You Haven’t Had the Scan Yet

If you’re reading this before booking, ask the provider five questions first:

  1. What share of your patients get at least one finding, and what share are told to get follow-up?
  2. Who explains results to me — a physician, live — and when?
  3. Do you use standardized follow-up recommendations (such as the ACR white papers) in your reports?
  4. Will I get my images, not just a report?
  5. What does follow-up typically cost, and will my own doctor need to order it?

Then decide knowing that the most likely outcome of the scan is not “all clear” but “some findings, most harmless, some requiring follow-up.” For more on the evidence behind whole-body screening, see our evidence review of preventive health scans, our comparison of Prenuvo, Neko Health, SimonMed, and Ezra, and our cancer-by-cancer guide to early detection, which covers the guideline-recommended screenings a whole-body MRI doesn’t replace.

The Bottom Line

A finding on a full-body MRI is the rule, not the exception. The most common ones — kidney cysts, liver hemangiomas, thyroid nodules, small pancreatic and adrenal findings, disc changes — are overwhelmingly benign, and radiology has spent the last decade building clear guidelines for exactly these situations, mostly to prevent unnecessary follow-up.

Your job isn’t to become a radiologist overnight. It’s to get the full report, find the recommendation line, sit down with your own doctor, anchor the plan to the published guideline, and know what “done” looks like. And if you’re shopping for coverage like life or disability insurance, know that the scan can follow you there — ideally before you book, not after.

Frequently Asked Questions

What should I do if my full-body MRI found something?

Don’t act on the report alone, and don’t search every term at midnight. Get the full written report (and ideally the images), note exactly what the radiologist recommended — no follow-up, routine follow-up, or urgent follow-up — and book a visit with your own primary care doctor to review it. Most findings on screening whole-body MRI are benign or low-risk, and professional guidelines from the American College of Radiology exist for nearly every common one, telling clinicians when follow-up is and isn’t needed.

How common are incidental findings on a full-body MRI?

Extremely common. A 2026 review from Weill Cornell radiologists reports that 78% to 97% of screening whole-body MRIs contain at least one reportable finding, with roughly 10% to 25% considered clinically significant. A 2018 BMJ meta-analysis of 27,643 people found potentially serious incidental findings in 3.9% of combined brain-and-body MRIs, and where outcomes were tracked, only about 1 in 5 of those turned out to be serious.

Is a kidney cyst found on MRI dangerous?

Usually not. Simple kidney cysts become more common with age — CT studies find them in roughly a quarter or more of adults over 50. Radiologists grade kidney cysts using the Bosniak classification (version 2019, which now includes MRI). Bosniak I and II cysts are benign and need no follow-up. Bosniak IIF cysts get periodic imaging for five years, and nearly all are benign. Only Bosniak III and IV warrant a urology consultation.

Will insurance pay for follow-up tests after a self-pay full-body MRI?

In the U.S., usually yes, as ordinary diagnostic care — but subject to your deductible, coinsurance, network rules, and sometimes prior authorization. The screening scan itself is almost never covered, but once a finding exists, the follow-up ultrasound, CT, specialist visit, or biopsy is typically billed to your insurance like any other diagnostic workup. Having your own in-network doctor order the follow-up makes approval much more likely.

Can a full-body MRI finding affect my life insurance?

It can. The Affordable Care Act bars U.S. health insurers from denying coverage or charging more for pre-existing conditions, but that protection does not extend to life, disability, or long-term care insurance. Those underwriters can ask about tests and pending workups, and an unresolved finding can lead them to postpone an application — commonly for months — until results are known. If you plan to buy such coverage anyway, it’s reasonable to do it before an elective scan; you must always answer application questions truthfully.

It means the radiologist sees something whose meaning depends on information they don’t have — your symptoms, history, labs, or prior imaging. It is not a coded warning that something is wrong. It’s a request for your doctor to interpret the finding in the context of you as a person, which is exactly why a report from a screening scan should be reviewed with a clinician who knows your history.

Should I get a second opinion on my full-body MRI?

It’s reasonable when a finding is labeled indeterminate, when the recommended follow-up is invasive (like a biopsy), or when the report seems out of step with the published guideline for that finding. Many academic radiology departments offer formal second reads of outside imaging. You’ll need your images, not just the report — under HIPAA’s right of access, you’re generally entitled to a copy.

How long does it take to know if an incidental finding is serious?

It depends on the finding. Some are resolved by a single targeted test within weeks — a thyroid ultrasound, or a dedicated adrenal MRI sequence. Others, like pancreatic cysts or Bosniak IIF kidney cysts, are managed with periodic imaging over years, because stability over time is itself the reassurance. Ask your doctor at the first visit what the end point of the follow-up is, so you know when you’re done.

This article is for general educational and informational purposes only. It is not medical, legal, or insurance advice, and it is not a substitute for diagnosis, treatment, or guidance from a licensed physician or other qualified professional. Guideline thresholds described here apply to typical cases in adults without symptoms or relevant cancer history; your clinician may appropriately recommend something different based on your individual situation. Insurance rules described reflect general U.S. practice as of September 2026 and vary by plan, insurer, and state. See our Methodology page for how we research and update articles like this one. If you have symptoms that feel like an emergency, seek emergency care.

Disclosure

ScanGlean does not sell scans, panels, or memberships, and we have no paid, affiliate, or referral relationship with any whole-body MRI provider, radiology group, or insurer mentioned in this article. If that changes, it will be disclosed here and on our Methodology page.

Sources

← Back to all guides

Newsletter

Before you go — get new comparisons first.

One email when we publish a new provider comparison, cost guide, or evidence review. No spam, no clinic promotions.